In the second pilot study, Shaw et al. demonstrated in a cohort of ALK-rearranged, crizotinib-resistant NSCLC patients an ORR of 48% (95% CI 36–60%) and an mPFS of 8.1 (95% CI 6.2–12.6) months [24]. Here, ALK is linked to non-small cell lung carcinoma.